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Abstract
Background: Lymph nodal involvement is very common in differentiated thyroid cancer, and in addition, cervical
lymph node micrometastases are observed in up to 80 % of papillary thyroid cancers. During the last decades, the
role of routine central lymph node dissection (RCLD) in the treatment of papillary thyroid cancer (PTC) has been an
object of research, and it is now still controversial. Nevertheless, many scientific societies and referral authors have
definitely stated that even if in expert hands, RCLD is not associated to higher morbidity; it should be indicated
only in selected cases.
Main body: In order to better analyze the current role of prophylactic neck dissection in the surgical treatment of
papillary thyroid cancers, an analysis of the most recent literature data was performed. Prophylactic or therapeutic
lymph node dissection, selective, lateral or central lymph node dissection, modified radical neck dissection, and
papillary thyroid cancer were used by the authors as keywords performing a PubMed database research. Literature
reviews, PTCs large clinical series and the most recent guidelines of different referral endocrine societies, inhering
neck dissection for papillary thyroid cancers, were also specifically evaluated. A higher PTC incidence was nowadays
reported in differentiated thyroid cancer (DTC) clinical series. In addition, ultrasound guided fine-needle aspiration
citology allowed a more precocious diagnosis in the early phases of disease. The role of prophylactic neck
dissection in papillary thyroid cancer management remains controversial especially regarding indications, approach,
and surgical extension. Even if morbidity rates seem to be similar to those reported after total thyroidectomy alone,
RCLD impact on local recurrence and long-term survival is still a matter of research. Nevertheless, only a selective
use in high-risk cases is supported by more and more scientific data.
Conclusions: In the last years, higher papillary thyroid cancer incidence and more precocious diagnoses were
worldwide reported. Among endocrine and neck surgeons, there is agreement about indications to prophylactic
treatment of node-negative “high-risk” patients. A recent trend toward RCLD avoiding radioactive treatment is still
debated, but nevertheless, prophylactic dissections in low-risk cases should be avoided. Prospective randomized
trials are needed to evaluate the benefits of different approaches and allow to drawn definitive conclusions.
Keywords: Total thyroidectomy, Papillary thyroid cancer, Prophylactic lymph node dissection, Routine central
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Background
Papillary thyroid cancer (PTC) is the most common
endocrine cancer, and during the last decades, its inci-
dence has worldwide increased, more than 240 % in the
USA in 2012. In PTCs localized to the thyroid gland, an
excellent survival is still reported with 5-year survival
rates >99 %. Lymph nodal involvement is very common,
and in up to 80 % of cases, lymph node micrometas-
tases are observed [1, 2]. Positive regional lymph nodes
decrease 5-year survival rates to 97 %, and in most
cases is associated to higher regional recurrence rates
[3]. Nevertheless, the impact of lymph node involve-
ment on local recurrence and survival is subject of
research trials [4–7]. Moreover, in the last decades,
thanks to a better sensitivity of cancer detection methods,
more efficacy of diagnostic imaging and molecular
markers, a precocious diagnosis allowed to identify a
higher number of node-negative low-risk patients, in
which the mean tumor size was mostly less than 2 cm, as
well as a sensible increase of microcarcinoma incidence
was reported in different series. Better outcomes, a favor-
able clinical evolution, a reduced locoregional recurrence
rate, and a prolonged survival are expected in these cases,
and consequently, a “tailored” and “less aggressive” man-
agement should be suggested to avoid an expensive and
risky “overtreatment”. However, according to more recent
literature data, in high-risk patients, lymphatic metastases
might affect survival, significantly increasing locoregional
relapse rate, while in low-risk cases they do not modify
the long-term outcomes [8].
The role of total thyroidectomy (TT) remains well-
established, while recently, a new substantial agreement
exists among endocrinologists regarding thyroid stimu-
lating hormone (TSH) suppression therapy and postop-
erative radioactive iodine (RAI) treatment [9].
A “low aggressive behavior” in most PTC patients, a low
locoregional recurrence rate, often an irrelevant mortality,
associated with a need of long-term follow-up (more than
20 years), makes difficult the indications to routine central
lymph node dissection (RCLD), in the absence of an
enlarged lymph node (preoperative ultrasound and intra-
operative inspection) in PTC ranging between 1 and 2 cm
of diameter. Considering the high risk of positive lymph
nodes, better outcomes and a lower morbidity rate associ-
ated with the first operation RCLD is suggested, even if
supposed higher morbidity rates are advocated by some
authors, in the absence of any demonstrable benefits in
terms of long-term survival [7]. In the management of dif-
ferentiated thyroid cancer (DTC), a routine lymph node
dissection may be selectively suggested with similar onco-
logic outcomes reported after more extensive and risky
dissections even if the literature review demonstrated that
indications to RCLD or to RAI ablation, in PTC ranging
between 1 and 2 cm of diameter, are a matter of intensive
research [10, 11]. According to the revised American
Thyroid Association (ATA) guidelines (2009), prophy-
lactic dissection in clinical node-negative patients, gen-
erally followed by lower postoperative thyroglobulin
(Tg) serum levels, may prevent a future recurrence,
allowing a lower morbidity rate than a second surgery
[9]. Nevertheless, even if a lower local recurrence is
generally advocated, statistically significant benefits in
terms of long-term survival and definitive evidence of
improved recurrence rates compared to TT alone were
not demonstrated [5, 7, 10]. In an attempt to better
clarify the current role of RCLD in treating PTC and
more intensively investigate its suitable indications, we
analyzed the most recent literature data.
Review section
By using as keywords lymph node dissection, selective,
lateral or central lymph node dissection, modified radical
neck dissection, prophylactic or therapeutic lymph node
dissection, and papillary thyroid cancer, a PubMed
database research was carried out limiting our search to
English language literature. Prospective, retrospective,
and meta-analysis studies were analyzed and in addition,
some older articles were considered. The most recent
guidelines regarding neck dissection for papillary thyroid
cancer, according to the American Thyroid Association
(ATA), European Thyroid Association (ETA), Unità
operative di Endocrinochirurgia (UEC), American Head
and Neck Society, and the American Academy of
Otolaryngology-Head and Neck Surgery, were also re-
ported. Regarding terminology of cervical lymphatic
anatomy (neck levels) and classification of neck dissec-
tion, the most recent ATA guidelines were considered
[9, 12]. Lymph node dissection benefits, complications,
and impact on locoregional recurrence rate and mortal-
ity were evaluated.
Discussion
DTC is an uncommon neoplasm, representing 2.5 % of
all malignancies, with an increasing mean annual inci-
dence per 100.000 individuals ranging from 1.2 to 2.6
in men and from 2.0 to 3.8 in women [13]. It is the fifth
most common cancer in women in the USA [1, 4]. In
the last decades, PTC incidence has increased more
than 240 %, and moreover, US-guided fine-needle aspir-
ation citology (FNAC) allowed a more precocious diag-
nosis. Papillary variants are by far the most frequent
neoplasms, followed by follicular (10 to 20 % of cases)
and medullary thyroid cancers (5 to 8 % of cases), often
part of MEN2 syndrome [14, 15]. Anaplastic thyroid
carcinoma represents a very rare and aggressive thyroid
neoplasm that belongs to the group of killer tumors,
with a mean survival period of 6.2 months, as reported
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for carcinosarcoma of other districts [16, 17]. Differ-
ently from the past, a higher number of small papillary
cancers (<1 cm) and a more precocious diagnosis are
reported in clinical series requiring a less aggressive
multimodal treatment [18, 19]. As a matter of fact, in
most PTC patients, prognosis is more and more favor-
able and is associated with a 10-year mortality rate of
about 7 % [20, 21]. However, about 20 % of patients
face the morbidity of locoregional recurrences, and
PTC-related deaths [22–24]. Macroscopic lymph node
involvement of central and lateral levels is very com-
mon in PTC, and micrometastases are observed in up
to 80 % of cases, especially in young patients [18]. Even
if some authors retain that they may be responsible for
thyroglobulin higher postoperative serum level, micro-
metastases do not affect the clinical course of most
PTC patients. Infiltration of thyroid capsule, patient age
(pediatric or geriatric population), tumor size, and
several oncogenes (p53, BRAF) are associated with
node involvement, representing the main risk factors
for recurrence [25]. Nevertheless, no clinical or patho-
logical factors might certainly predict lymph node
metastases. The observed discordance between the high
rate of lymph node micrometastases, and the low
incidence of clinical recurrence following TT without
RCLD, may be correlated to postoperative RAI admin-
istration but testifies the indolent PTC nature.
Nevertheless, recently, it has been hypothesized that,
especially in older patients, lymphatic metastases may
affect recurrence and survival rates. In the treatment of
low-risk clinically node-negative DTC patients with a
cancer exceeding 10 mm of diameter, TT should be con-
sidered as the operation of choice, as in most thyroid
diseases [26–28]. In addition, there is agreement about
RCLD indications in high-risk patients—defined as male
patient, age >45 years, T > 3 cm, and BRAF-positive. On
the contrary, the role of RCLD in low-risk cases is to date
under investigation, and endocrine and neck surgeons are
divided between pros and cons. According to its propo-
nents, a better chance of cure, reducing the recurrence
risk, may be achieved with a low morbidity. Moreover, the
high incidence of lymph node metastases, the observation
that reoperation for central recurrence may have a greater
morbidity, the insufficient diagnostic accuracy of intraop-
erative inspection and of ultrasonography, reported in 1/3
of DTC patients, and the failure of 131I ablation in about
30 % of cases, are considered in favor of RCLD. The pro-
cedure allows a better staging too, but a prospective ran-
domized study of RCLD could be very expensive and not
readily feasible [29]. ATA guidelines, published in 2006,
stated that RCLD should be considered in DTC, but this
recommendation is not based on strong supporting data
[30]. Recently, according to ATA and UEC, prophylactic
dissection could be especially undertaken in high-risk
patients with advanced primary tumors, so recognizing
that this approach may be associated with increased
morbidity, especially among low-volume surgeons [9,
31]. Rates of permanent hypoparathyroidism and of un-
intentional permanent recurrent laryngeal nerve injury
after TT were, respectively, 1–2 and 0–5.5 %, whereas
following TT associated with RCLD, they, respectively,
increased to 0–14.3, and to 0–5.7 %, according to ML
White et al. [32]. The author concluded that central
nodal dissection reduces locoregional recurrence, im-
proves disease-free survival, and increases the number
of patients with undetectable Tg levels, although is
associated with a higher risk of injury to parathyroid
glands. In case of unilateral cancer, with the aim to
reduce RCLD morbidity, some authors, as alternative
approach, proposed ipsilateral procedure with variable
results [33]. This recent proposal appears to be very
interesting, but conclusive data have still not been
reported. Pacini et Al., stated that even if associated to
a better staging, RCLD does not offer yet further bene-
fits [34]. A prospective randomized study of RCLD is
very expensive and not readily feasible and so, without
sufficient statistical power to demonstrate significant
differences in outcomes, the role of prophylactic sur-
gery is still to be demonstrated [29]. A better cancer
staging and sensible reduction of postoperative serum
Tg levels is really expected, but prospective randomized
trials are needed to evaluate the benefits of prophylactic
dissection [35]. TT, followed by RAI administration and
TSH suppression therapy, may guarantee optimal long-
term results, with a low incidence of locoregional lymph
node recurrence [8]. Regarding reoperation (lymph node
dissection) outcomes, a higher morbidity is not reported
especially following unilateral procedures [5]. Neverthe-
less, RCLD seems to have a role in DTC staging and is
useful to modify the treatment protocol. Travagli et al.
reported a 30 % increase in the number of patients with
T1 DTC (preoperatively considered node-negative), for
whom 131I ablation was indicated following routine central
dissection, demonstrating unexpected nodal metastases
[25]. In the absence of an enlarged lymph node, and espe-
cially when RAI administration is advisable, routine
lymph node dissection is not indicated [36–38]. More-
over some authors reported a significative incidence of
lateral lymph node relapse that was unaffected by
routine central dissection [39]. On the other hand, in
low-risk patients with tumors ≤1 cm, lymph node
dissection may however discover metastases requiring
RAI ablation.
Conclusions
The role of routine neck dissection remains a matter of re-
search, and the frequent lateral postoperative involvement
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might be cited against its supposed benefits, avoiding risky
morbidity.
In the absence of data supporting the favorable effects
of RCLD, we believe that, in the treatment of PTC
without a suspicious enlarged lymph node, it is not in-
dicated, and more prospective, randomized controlled
studies with large sample and sufficient follow-up are
needed in the attempt to better define its clinical
significance and demonstrate its prognostic impact. In
addition, in identifying high-risk patients, more accur-
ate and definite criteria might be investigated for a better
preoperative assessment and a tailored surgery.
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